Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Myomo Inc (MYO)

Myomo Inc (MYO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,941
  • Shares Outstanding, K 5,583
  • Annual Sales, $ 7,580 K
  • Annual Income, $ -11,560 K
  • 60-Month Beta 1.53
  • Price/Sales 7.47
  • Price/Cash Flow N/A
  • Price/Book 4.11
Trade MYO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.69
  • Number of Estimates 3
  • High Estimate -0.58
  • Low Estimate -0.77
  • Prior Year -2.51
  • Growth Rate Est. (year over year) +72.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.61 +3.42%
on 04/16/21
14.50 -31.46%
on 03/22/21
-4.14 (-29.41%)
since 03/19/21
3-Month
9.61 +3.42%
on 04/16/21
18.88 -47.36%
on 02/16/21
-0.83 (-7.72%)
since 01/20/21
52-Week
3.42 +190.61%
on 06/11/20
18.88 -47.36%
on 02/16/21
+6.02 (+153.54%)
since 04/20/20

Most Recent Stories

More News
Myomo Participates in Ground-breaking Brain-computer Interface Trial

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis,...

MYO : 9.95 (-0.70%)
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 21.28% and 14.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

MYO : 9.95 (-0.70%)
Myomo, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 10, 2021 / Myomo, Inc. (AMEX:MYO) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 10, 2021 at 4:30 PM Eastern...

MYO : 9.95 (-0.70%)
Myomo to Participate in Three Investment Conferences During the Month of March

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis,...

MYO : 9.95 (-0.70%)
Myomo to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis,...

MYO : 9.95 (-0.70%)
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MYO : 9.95 (-0.70%)
Illumina (ILMN) Sequencing & Microarray Sales Hurt by Pandemic

Seasonality in DTC functionality also continues to erode Illumina's (ILMN) microarray sales.

ILMN : 397.61 (-1.63%)
ABT : 119.81 (-3.79%)
MYO : 9.95 (-0.70%)
APYX : 9.68 (+0.41%)
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical

The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical

BDX : 257.34 (-0.63%)
ABT : 119.81 (-3.79%)
MYO : 9.95 (-0.70%)
APYX : 9.68 (+0.41%)
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test

BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.

BDX : 257.34 (-0.63%)
ABT : 119.81 (-3.79%)
MYO : 9.95 (-0.70%)
APYX : 9.68 (+0.41%)
Germany's Largest Statutory Health Insurance Company Approves MyoPro

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis,...

MYO : 9.95 (-0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Myomo, Inc. is a commercial stage medical robotics company. It offers expanded mobility which suffering from neurological disorders and upper limb paralysis. The company develops and markets the MyoPro(R) product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed...

See More

Key Turning Points

3rd Resistance Point 10.68
2nd Resistance Point 10.43
1st Resistance Point 10.23
Last Price 9.95
1st Support Level 9.78
2nd Support Level 9.53
3rd Support Level 9.33

See More

52-Week High 18.88
Fibonacci 61.8% 12.97
Fibonacci 50% 11.15
Last Price 9.95
Fibonacci 38.2% 9.33
52-Week Low 3.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar